Drug Price Hikes Continue Despite Scrutiny: What Patients Can Expect in 2026
Despite increased political pressure and recent negotiations aimed at lowering costs, pharmaceutical companies are planning price increases on hundreds of prescription drugs in 2026. Data from healthcare research firm 3 Axis Advisors reveals at least 350 branded medications will see price hikes, including vital vaccines for COVID-19, RSV, and shingles, alongside blockbuster cancer treatments like Ibrance.
A Growing Trend: Price Increases Outpace Reductions
This isn’t an isolated incident. The number of planned price increases is actually up from last year, when over 250 drugs were slated for cost adjustments. The median price increase is holding steady around 4%, mirroring 2025 levels. This suggests a continued pattern of manufacturers seeking to maximize revenue, even in the face of public and governmental pushback.
It’s crucial to understand these increases represent list prices and don’t account for rebates offered to pharmacy benefit managers (PBMs) or other discounts. The final cost to the patient can vary significantly depending on their insurance coverage and negotiation power of their PBM.
The Jardiance Paradox: Negotiated Savings, Continued Increases Elsewhere
The situation is complex. While the U.S. government successfully negotiated lower prices for some drugs under the Inflation Reduction Act – notably Jardiance, a medication for diabetes and heart failure – this hasn’t halted price increases across the board. Boehringer Ingelheim and Eli Lilly, the co-marketers of Jardiance, slashed the price by two-thirds for Medicare beneficiaries, but are still raising prices on other medications in their portfolios.
Did you know? The U.S. consistently pays significantly more for prescription drugs than other developed nations – often nearly three times as much.
Trump’s Influence and the Illusion of Deals
Former President Trump has been vocal about his desire to lower drug prices, and has brokered deals with 14 drugmakers offering discounts for Medicaid and cash-paying customers. However, experts argue these deals are largely symbolic.
“These deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.,” explains Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston. He suggests companies are strategically maximizing list prices while simultaneously negotiating complex discounts behind the scenes.
Pfizer Leads the Charge: Which Drugs Are Affected?
Pfizer is planning the most extensive list of price hikes, impacting around 80 different drugs. This includes Ibrance (cancer), Nurtec (migraine), and Paxlovid (COVID-19), as well as essential hospital medications like morphine and hydromorphone. While most increases are under 10%, the COVID-19 vaccine, Comirnaty, will see a 15% jump, and some older, inexpensive hospital drugs are facing price increases exceeding 400%.
Pfizer defends these increases, stating they are necessary to fund continued research and development and address rising business costs. “The modest increase is necessary to support investments that allow us to continue to discover and deliver new medicines as well as address increased costs throughout our business,” a company statement reads.
Why Are Prices Still Rising? The Complexities of the Pharmaceutical Market
Several factors contribute to this ongoing trend. The pharmaceutical industry operates within a complex web of regulations, research costs, and market dynamics. High research and development expenses are often cited as justification for high prices, but critics argue that marketing and administrative costs also play a significant role.
Pro Tip: Utilize prescription drug discount cards and compare prices at different pharmacies to potentially save money on your medications. Resources like GoodRx can be helpful.
The Impact of Inflation and Government Policies
While large-scale price increases have become less common due to criticism and new policies – such as penalties for Medicare price hikes exceeding inflation – manufacturers are still finding ways to adjust prices. The Inflation Reduction Act is beginning to have an effect, but its impact will be gradual.
GSK plans to increase prices on around 20 drugs and vaccines, citing the need to support scientific innovation. Sanofi and Novartis have yet to comment on their pricing strategies.
Looking Ahead: What to Expect in Early 2026
January historically marks the peak season for drug price increases. Expect further announcements in the coming weeks as pharmaceutical companies finalize their pricing strategies for the year. The interplay between government regulations, manufacturer strategies, and patient needs will continue to shape the landscape of prescription drug costs.
Frequently Asked Questions (FAQ)
- Why are drug prices so high in the U.S.? Several factors contribute, including high research and development costs, marketing expenses, limited competition, and a complex regulatory environment.
- What is the Inflation Reduction Act doing to lower drug prices? The Act allows Medicare to negotiate prices for some high-cost drugs and penalizes companies that raise prices faster than inflation.
- Can I get help paying for my prescription drugs? Yes, resources like prescription drug discount cards, patient assistance programs, and government programs can help reduce your costs.
- Will drug prices continue to rise? While the rate of increases may moderate, experts anticipate continued price adjustments as pharmaceutical companies navigate a changing market.
Want to stay informed about healthcare costs and policy changes? Subscribe to our newsletter for the latest updates and insights.
Related reading